ENL
ENL
ENL - Enaleni Pharmaceuticals - Trading update
Enaleni Pharmaceuticals Limited
(Incorporated in the Republic of South Africa)
(Registration number 2002/018027/06)
(JSE code: ENL & ISIN: ZAE000067740)
("Enaleni" or "the company")
Trading update
Shareholders are advised that, for the six months ended 30 June 2008, Enaleni
expects basic and fully diluted earnings per share (EPS) to be between 21%-31%
higher and basic and fully diluted headline earnings per share (HEPS) to be
between 5%-15% higher than the prior comparative period.
The above information has not been reviewed by the company`s auditors and the
company`s interim results for the six months ended 30 June 2008 are expected to
be published on 9 September 2008.
Durban
21 August 2008
Sponsor
Nedbank Capital
Date: 21/08/2008 16:41:00 Produced by the JSE SENS Department.
The SENS service is an information dissemination service administered by the
JSE Limited (`JSE`). The JSE does not, whether expressly, tacitly or
implicitly, represent, warrant or in any way guarantee the truth, accuracy or
completeness of the information published on SENS. The JSE, their officers,
employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature,
howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.
Profile Group (Pty) Ltd. has taken care in preparing all information on this website, but does not accept any liability for errors or out-of-date information.
